Spots Global Cancer Trial Database for A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
Official Title: A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)
Study ID: NCT01907529
Conditions
Study Description
Brief Summary: The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer patients. The hypothesis of this protocol is that the combined an active angiogenesis agent to chemotherapy could enhance the pathological responce rate and further benefit breast cancer patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, China, Shijiazhuang, Hebei, China
Contact Details
Name: YUNJIANG LIU, M.D.& PhD.
Affiliation: The Fourth Hospital of Hebei Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
